Biotech entity
pharma is the sole category represented across all 1 tracked stories. Chemotherapy-induced myelosuppression (CIM) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Cosela (trilaciclib) appears in 1 tracked Biotech story from July 27, 2026.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Chemotherapy-induced myelosuppression (CIM) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Cosela (trilaciclib) appears in 1 tracked Biotech story from July 27, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cosela (trilaciclib). Shared-story counts are live from our verified record — not editorial picks.
Partnership Announcement
Menarini Asia-Pacific and Pharmacosmos announce exclusive licensing and distribution agreement for Cosela in 11 APAC markets.
Pharmacosmos partners with Menarini to commercialize trilaciclib (Cosela), the first FDA-approved prophylactic therapy for chemotherapy-induced myelosuppression, across 11 Asia-Pacific markets, marking a significant geographic expansion for the first-in-class agent.
Source: vietnamtribune.com · thehindu.com
Cosela (trilaciclib) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
